Aldeyra Therapeutics is a biotechnology company engaged in developing and commercializing medicines for patients with immune-mediated diseases. The company's primary product candidate, reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. The company has additional product candidates in development for proliferative vitreoretinopathy and other retinal diseases, autoimmune disease, and cancer. The company has discovered and are developing two additional reactive aldehyde species inhibitors, ADX-103 and ADX-629, for the treatment of retinal disease and autoimmune disease, respectively.

Barnwell Industries is engaged in the business of: acquiring, developing, producing and selling oil and natural gas in Canada including evaluating proposals by third parties with regard to participation in exploratory and developmental operations elsewhere; investing in land interests in Hawaii; and drilling water and water monitoring wells of varying depths in Hawaii, installing and repairing water pumping systems through its wholly-owned subsidiary, Water Resources International, Inc., which is the distributor for Floway pumps and equipment in the state of Hawaii.

Citi Trends is a retailer of fashion apparel and accessories for the entire family. The company also provides a variety of products from less recognized brands and a lesser amount representing private label products under its brands. The company's merchandise includes apparel, accessories and home. Within apparel, the company provides fashion sportswear for men, women and children, including offerings for newborns, infants, toddlers, boys and girls. Accessories include handbags, jewelry, footwear, belts, intimate apparel, scrubs and sleepwear. Home includes functional bedroom, bathroom and kitchen products, as well as beauty and toys.

DocuSign provides e-signature solution as the main part of its cloud software suite for automating the agreement process. The company calls its suite the DocuSign Agreement Cloud. The DocuSign Agreement Cloud is designed to allow companies of various sizes and across various industries to make agreement, approval process, or transaction digital, from practically any device, from almost anywhere in the world.

Funko is holding company. Through its subsidiaries, the company is a pop culture consumer products company. The company sells various licensed pop culture consumer products featuring characters from a range of media and entertainment content, including movies, TV shows, video games, music and sports. The company's product categories include: Figures, which includes figures that celebrate pop culture icons in the form of stylized vinyl, blind-packed miniatures and action figures; and Other, which includes plush products that are soft-sculpt figures; apparel (including t-shirts and hats); homewares (including drinkware, party lights and other home accessories); and stylized bags, purses and wallets and board games.

Re/Max Holdings is a holding company. The company's only business is to act as the sole manager of RMCO, LLC. The company is a franchisor in the real estate industry, franchising real estate brokerages globally under the RE/MAX (RE/MAX) brand, and mortgage brokerages within the U.S. under the Motto Mortgage (Motto) brand. RE/MAX and Motto are fully franchised - the company does not own any of the brokerages that operate under these brands. All of the RE/MAX branded brokerage office locations are being operated by franchisees. The company operates under the following three segments: RE/MAX Franchising, Motto Franchising and booj.

Scholar Rock is a biopharmaceutical company. The company's primary product candidate, SRK-015, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. The company's second product candidate is SRK-181 and is being developed for the treatment of cancers resistant to checkpoint blockade therapies, such as anti-PD1 antibodies. The company's third antibody program targets the signaling of bone morphogenetic protein 6, another member of the TGF? superfamily, which is involved in a set of biological processes in various parts of the body.